Abstracts 7.6; 37% female, 63% male) participated in a health examination which included a lipid profi le. An index date was assigned for each study participant using the date of their exam and statin medication usage was determined through the pharmacy claims database for 365 days before the index date. Patients were identifi ed as adherent to statins if their medication possession ratio (MPR) was at least 80%. RESULTS: Statin use increased over the study period with 150 (9.3%) executives fi lling at least one statin prescription in the 365 days prior to their exam. A total of 102 statin users (68%) were adherent to statin medication. Among all patients who received statin treatment, 70% (OR 2.33, 95% CI 1.54, 3.51) achieved near optimal ( 130 mg/ dL) and 30% (OR 1.78, 95% CI 1.15, 2.76) achieved optimal ( 100 mg/dL) LDL-C goals which are signifi cantly higher than the rates among statin non-users (55% and 21%). Both adherent statin users and nonadherent statin users were more likely to achieve recommended near optimal LDL-C goals compared to executives who were not taking statins (overall p 0.002; adherent: OR 2.75, 95%CI 1.662, 4.550; nonadherent: OR 1.70, 95% CI 0.884, 3.268.) CONCLUSIONS: Among executives who participated in a periodic health examination, statin usage appears to be associated with improvements in LDL-C goal attainment. Appropriate medication usage and adherence to medication should be encouraged in working populations. OBJECTIVES: To determine the effect of ACE Inhibitors/ARBs and statins on the incidence of dementia, in patients with Chronic Heart Failure (CHF). METHODS: A national retrospective cohort of Veterans Affairs (VA) patients, with at least one outpatient claim of CHF from . Patients with non-utilization of VA services for two years and prevalent cases of dementia were excluded. A Cox proportional hazards model of time to dementia diagnosis was constructed to test the association of drug use with dementia, adjusted for socio-demographics, co-morbidities and co-medications. RESULTS: Out of 242,734 patients, 2.77% developed dementia during follow-up. About 75% were elderly and 79% had hypertension. Females, African-Americans had signifi cantly higher risk of dementia than males, whites, respectively. Risk of dementia increased progressively with age. In adjusted analyses, hypertension (HR: 1.157, 95% CI: 1.078-1.240), diabetes (HR: 1.105, 95% CI: 1.051-1.161), and cerebrovascular disease (HR: 1.577, 95% CI: 1.489-1.671) signifi cantly increased risk of dementia. Adjusted analyses of one-year (HR: 0.988, 95% CI: 0.911-1.071) or two-year (HR: 0.991, 95% CI: 0.930-1.057) exposure to ACE Inhibitors did not signifi cantly affect dementia. Adjusted analyses of oneyear exposure to ARBs (HR: 0.784, 95% CI: 0.634-0.969), statins (HR: 0.906, 95% CI: 0.839-0.979) and two-year exposure to ARBs (HR: 0.711, 95% CI: 0.594-0.852), statins (HR: 0.884, 95% CI: 0.829-0.943) had protective effect on incidence of dementia. Two-year drug exposure had increased protective effect, compared to one-year exposure. CONCLUSIONS: Study suggests potential benefi cial effects, to delay onset of dementia, associated with use of ARBs and statins. Thus, prescribing of such agents in pharmacotherapeutic regimens of CHF patients should be encouraged.
Unfortunately, CHD could be a silent disease until the manifestations occur. Therefore, early detection and control of cardiovascular risk factors including cholesterol and blood pressure is vital. In view of this point, the current project aimed to investigate the 10-year cardiovascular risk in the general public of Hong Kong. METHODS: A 12-month prospective public screening of lipid panels and blood pressure for the estimation of 10-year cardiovascular risk was conducted in the general public of Hong Kong between April 2007 and April 2008. RESULTS: During this period, a total of 2,607 patients were recruited with the mean age of 46.4 / 11.1 years old (51.3% male) and 8.1% of subjects were active smokers. Among all of the subjects, the mean total cholesterol was 5.42 / 1.28 mmol/L and the mean high density cholesterol was 1.59 / 0.75 mmol/L. The mean systolic blood pressure was 121.7 / 19.5 mmHg. The assessment of the 10-year cardiovascular risk showed that 13.8% of the subjects were moderately high to high risk patients. CONCLUSIONS: The project demonstrated that the general public in Hong Kong had relatively high total cholesterol and normalhigh systolic blood pressure. There were almost 2 in every 10 Hong Kong citizens may have a 10-20% or more than 20% risk to develop CHD in the next 10 years. As a result, good lifestyle modifi cation and regular health screening are essential and urgently required to lower the cardiovascular risk in the general public of Hong Kong.
PCV21 PREVALENCE, AWARENESS, AND MANAGEMENT OF HYPERTENSION, DYSLIPIDEMIA, AND DIABETES AMONG UNINSURED AND INSURED ADULTS IN THE UNITED STATES
McDonald M 1 , Hertz RP 1 , Lustik MB 2 , Unger AN 1 1 Pfi zer, New York, NY, USA, 2 Science Applications International Corporation, Reston, VA, USA OBJECTIVES: National estimates of cardiovascular risk factor prevalence, awareness, treatment, and control among adults without health insurance are lacking. This study contributes to our knowledge by examining current national estimates for hypertension, dyslipidemia, and diabetes among uninsured, non-Medicaid insured, and Medicaid-insured adults aged 18 through 64 years. METHODS: Cross-sectional observational study design. Analysis of adults 18 through 64 years of age surveyed in the National Health and Nutrition Examination Survey (NHANES) 2003-2006 (N 8,500) . RESULTS: Of an estimated 178.6 million working-age adults, 21.8% (95% confi dence interval [CI] 19.6%-24.1%) lack health insurance. Hypertension prevalence is signifi cantly lower in the uninsured compared with the non-Medicaid insured (18.9% and 21.8%, age and gender adjusted) as are rates of awareness (62.8% vs 77.0%) and treatment (43.9% vs 65.5%). Medicaid-insured adults have a signifi cantly higher prevalence of hypertension (29.1%) than the non-Medicaid insured. There is no signifi cant difference between the uninsured and non-Medicaid insured with respect to adjusted prevalence of dyslipidemia (27.4% and 25.3%) or type-2 diabetes (6.4% and 6.0%). Awareness and treatment rates for dyslipidemia are signifi cantly lower in the uninsured compared with the non-Medicaid insured (38.8% vs 64.7% for awareness; 18.0% vs 41.4% for treatment). Treatment rates for diabetes are also significantly lower for the uninsured (39.9% vs 62.5%). Multivariable logistic regression controlling for age, gender, race, education, access to care, and marital status indicate that the uninsured are signifi cantly less likely than the non-Medicaid insured to be aware of and treated for their dyslipidemia and less likely to be treated for their diabetes. CONCLUSIONS: Dyslipidemia and diabetes are less likely to be detected or treated among the uninsured compared with the non-Medicaid insured, calling for effective approaches to reduce these disparities.
